VBL Therapeutics, a clinical-stage biotechnology company committed to the development of novel treatments for immune-inflammatory diseases and cancer, announced that the company will present preclinical data from its lead program, VB-201, at the Keystone Symposium on Bioactive Lipids: Biochemistry and Diseases. Eyal Breitbart, Ph.D., vice president, research at VBL is scheduled to present a poster entitled "Lecinoxoids - Novel Anti-inflammatory Oxidized Phospholipids" on Monday, June 7, 2010 at 12:30 p.m. JST in Kyoto, Japan.
The Keystone Symposium on Bioactive Lipids: Biochemistry and Diseases is a forum for scientists to share their progress in lipid mediators and the translation from model systems to an understanding of their role in human physiology, disease and drug action. Keystone Symposia are recognized as catalysts for advancing biomedical and life sciences by connecting scientists within and across disciplines in an environment conducive to information exchange, the generation of new ideas, and acceleration of applications that benefit society.
VB-201 is the first in a new class of drugs and the lead candidate of several proprietary phospholipid analogs from VBL's proprietary Lecinoxoid family that were designed to be orally available, anti-inflammatory medicines. VB-201 has successfully completed four Phase 1 clinical trials involving 120 healthy subjects under a U.S. investigational new drug (IND) application. These Phase 1 trials demonstrated that VB-201 was well tolerated with a favorable safety profile. Preclinical studies indicate that VB-201 has significant potential to treat inflammation in chronic diseases such as psoriasis, rheumatoid arthritis, multiple sclerosis, inflammatory bowel disease, and also found to bring about regression of atherosclerosis. VB-201 is currently being evaluated in a Phase 2 efficacy and safety study for the treatment of patients with psoriasis.
Source
VBL Therapeutics
Комментариев нет:
Отправить комментарий